A phase II study of ABT-751 in patients with advanced non-small cell lung cancer

Ann M. Mauer, Ezra E.W. Cohen, Patrick C. Ma, Mark F. Kozloff, Lee Schwartzberg, Andrew I. Coates, Jiang Qian, Anne E. Hagey, Gary B. Gordon

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

PURPOSE: To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS: Eligibility was limited to patients with recurrent or metastatic NSCLC who had received one to two cytotoxic chemotherapy regimens, had a performance status of zero to one, and adequate organ function. Treatment included ABT-751 200 mg daily for 21 consecutive days, followed by 7 days off drug. Objectives were to determine response rate, time to tumor progression, survival, and tolerability of ABT-751. RESULTS: All 35 enrolled patients were assessable for survival, response, and tolerability. Median time to tumor progression and overall survival were 2.1 and 8.4 months, respectively. The objective response rate was 2.9%. One patient achieved a partial response that was ongoing 567 days after initial documentation. Treatment was well tolerated; fatigue, constipation, and dehydration were the only treatment related, grade three adverse events occurring in more than one patient. Incidence of grade 3/4 hematologic and blood chemistry toxicities was acceptable, and ABT-751 was not associated with myelosuppression. CONCLUSIONS: ABT-751 associated toxicity was acceptable. The median time to progression and overall survival as demonstrated for ABT-751 were comparable to other agents considered active in this patient population and to current treatments approved for second-line NSCLC. The novel antimitotic targeting of ABT-751 in combination with the compound's acceptable nonmyelosuppressive toxicity profile and efficacy similar to agents currently in use in this setting, warrant further evaluation of this compound in combination with other cytotoxic agents in advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)631-636
Number of pages6
JournalJournal of Thoracic Oncology
Volume3
Issue number6
DOIs
StatePublished - Jan 1 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Antimitotic Agents
Survival
Cytotoxins
Constipation
Therapeutics
ABT751
Dehydration
Microtubules
Polymerization
Documentation
Fatigue
Neoplasms
Drug Therapy
Incidence
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Mauer, A. M., Cohen, E. E. W., Ma, P. C., Kozloff, M. F., Schwartzberg, L., Coates, A. I., ... Gordon, G. B. (2008). A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology, 3(6), 631-636. https://doi.org/10.1097/JTO.0b013e318174e01f

A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. / Mauer, Ann M.; Cohen, Ezra E.W.; Ma, Patrick C.; Kozloff, Mark F.; Schwartzberg, Lee; Coates, Andrew I.; Qian, Jiang; Hagey, Anne E.; Gordon, Gary B.

In: Journal of Thoracic Oncology, Vol. 3, No. 6, 01.01.2008, p. 631-636.

Research output: Contribution to journalArticle

Mauer, AM, Cohen, EEW, Ma, PC, Kozloff, MF, Schwartzberg, L, Coates, AI, Qian, J, Hagey, AE & Gordon, GB 2008, 'A phase II study of ABT-751 in patients with advanced non-small cell lung cancer', Journal of Thoracic Oncology, vol. 3, no. 6, pp. 631-636. https://doi.org/10.1097/JTO.0b013e318174e01f
Mauer, Ann M. ; Cohen, Ezra E.W. ; Ma, Patrick C. ; Kozloff, Mark F. ; Schwartzberg, Lee ; Coates, Andrew I. ; Qian, Jiang ; Hagey, Anne E. ; Gordon, Gary B. / A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. In: Journal of Thoracic Oncology. 2008 ; Vol. 3, No. 6. pp. 631-636.
@article{6f85edd21d8e4ef3a7ed448638a3b18b,
title = "A phase II study of ABT-751 in patients with advanced non-small cell lung cancer",
abstract = "PURPOSE: To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS: Eligibility was limited to patients with recurrent or metastatic NSCLC who had received one to two cytotoxic chemotherapy regimens, had a performance status of zero to one, and adequate organ function. Treatment included ABT-751 200 mg daily for 21 consecutive days, followed by 7 days off drug. Objectives were to determine response rate, time to tumor progression, survival, and tolerability of ABT-751. RESULTS: All 35 enrolled patients were assessable for survival, response, and tolerability. Median time to tumor progression and overall survival were 2.1 and 8.4 months, respectively. The objective response rate was 2.9{\%}. One patient achieved a partial response that was ongoing 567 days after initial documentation. Treatment was well tolerated; fatigue, constipation, and dehydration were the only treatment related, grade three adverse events occurring in more than one patient. Incidence of grade 3/4 hematologic and blood chemistry toxicities was acceptable, and ABT-751 was not associated with myelosuppression. CONCLUSIONS: ABT-751 associated toxicity was acceptable. The median time to progression and overall survival as demonstrated for ABT-751 were comparable to other agents considered active in this patient population and to current treatments approved for second-line NSCLC. The novel antimitotic targeting of ABT-751 in combination with the compound's acceptable nonmyelosuppressive toxicity profile and efficacy similar to agents currently in use in this setting, warrant further evaluation of this compound in combination with other cytotoxic agents in advanced NSCLC.",
author = "Mauer, {Ann M.} and Cohen, {Ezra E.W.} and Ma, {Patrick C.} and Kozloff, {Mark F.} and Lee Schwartzberg and Coates, {Andrew I.} and Jiang Qian and Hagey, {Anne E.} and Gordon, {Gary B.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1097/JTO.0b013e318174e01f",
language = "English (US)",
volume = "3",
pages = "631--636",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - A phase II study of ABT-751 in patients with advanced non-small cell lung cancer

AU - Mauer, Ann M.

AU - Cohen, Ezra E.W.

AU - Ma, Patrick C.

AU - Kozloff, Mark F.

AU - Schwartzberg, Lee

AU - Coates, Andrew I.

AU - Qian, Jiang

AU - Hagey, Anne E.

AU - Gordon, Gary B.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - PURPOSE: To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS: Eligibility was limited to patients with recurrent or metastatic NSCLC who had received one to two cytotoxic chemotherapy regimens, had a performance status of zero to one, and adequate organ function. Treatment included ABT-751 200 mg daily for 21 consecutive days, followed by 7 days off drug. Objectives were to determine response rate, time to tumor progression, survival, and tolerability of ABT-751. RESULTS: All 35 enrolled patients were assessable for survival, response, and tolerability. Median time to tumor progression and overall survival were 2.1 and 8.4 months, respectively. The objective response rate was 2.9%. One patient achieved a partial response that was ongoing 567 days after initial documentation. Treatment was well tolerated; fatigue, constipation, and dehydration were the only treatment related, grade three adverse events occurring in more than one patient. Incidence of grade 3/4 hematologic and blood chemistry toxicities was acceptable, and ABT-751 was not associated with myelosuppression. CONCLUSIONS: ABT-751 associated toxicity was acceptable. The median time to progression and overall survival as demonstrated for ABT-751 were comparable to other agents considered active in this patient population and to current treatments approved for second-line NSCLC. The novel antimitotic targeting of ABT-751 in combination with the compound's acceptable nonmyelosuppressive toxicity profile and efficacy similar to agents currently in use in this setting, warrant further evaluation of this compound in combination with other cytotoxic agents in advanced NSCLC.

AB - PURPOSE: To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS: Eligibility was limited to patients with recurrent or metastatic NSCLC who had received one to two cytotoxic chemotherapy regimens, had a performance status of zero to one, and adequate organ function. Treatment included ABT-751 200 mg daily for 21 consecutive days, followed by 7 days off drug. Objectives were to determine response rate, time to tumor progression, survival, and tolerability of ABT-751. RESULTS: All 35 enrolled patients were assessable for survival, response, and tolerability. Median time to tumor progression and overall survival were 2.1 and 8.4 months, respectively. The objective response rate was 2.9%. One patient achieved a partial response that was ongoing 567 days after initial documentation. Treatment was well tolerated; fatigue, constipation, and dehydration were the only treatment related, grade three adverse events occurring in more than one patient. Incidence of grade 3/4 hematologic and blood chemistry toxicities was acceptable, and ABT-751 was not associated with myelosuppression. CONCLUSIONS: ABT-751 associated toxicity was acceptable. The median time to progression and overall survival as demonstrated for ABT-751 were comparable to other agents considered active in this patient population and to current treatments approved for second-line NSCLC. The novel antimitotic targeting of ABT-751 in combination with the compound's acceptable nonmyelosuppressive toxicity profile and efficacy similar to agents currently in use in this setting, warrant further evaluation of this compound in combination with other cytotoxic agents in advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=44649138596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649138596&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318174e01f

DO - 10.1097/JTO.0b013e318174e01f

M3 - Article

VL - 3

SP - 631

EP - 636

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -